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     Home Parenteral Nutrition (HPN), a common nutritional support therapy, corrects for nutrient 
imbalances caused by a malfunctioning gastrointestinal tract outside a medical in patient setting. 
Patients utilizing HPN face psychosocial challenges, particularly depression, that go undetected 
due to their confinement within a home environment and lack daily interactions with healthcare 
professionals.  Telemedicine, as a mode of treatment, can assist healthcare professionals in the 
detection of depression.  In the current study, raters coded 25 long-term HPN patients in 
facilitated group discussions with the modified Raskin scale (a 21-item observer rating scale) to 
assess the feasibility of utilizing a technology- supported platform to identify depressive 
symptomatology within a chronically ill population. Results showed the modified Raskin appears 
to have predictive but not concurrent validity.  Thus, the modified Raskin scale showed promise 
as a tool for healthcare professionals, who wish to use telemedicine as a treatment avenue to 
detect and monitor depression amongst long-term HPN patients.  
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Assessing the Feasibility of Using Telemedicine to Identify Depressive Symptomatology within 
the Long-Term Home Parenteral Nutrition Population 
     Nutrition support therapies are required for multiple underlying pathologies that cause 
malnutrition and nutrient imbalance (Kirby, 2012).  Home Parenteral Nutrition (HPN), a 
nutrition support therapy, addresses the nutrient imbalance specifically caused by a 
malfunctioning gastrointestinal tract and increases life expectancy outside of a medical inpatient 
care setting and within a home environment  (Baxter, Fayers, & McKinlay, 2006; Huisman-de 
Waal, Schoonhoven, Jansen, Wanten, & van Achterberg, 2007; Persoon et al., 2005).  Limited 
epidemiological data exist regarding HPN use within the United States.  However, previous data 
collected from 1989 to 1992 showed that 120 per 100,000 individuals utilized HPN (DiBaise & 
Scolapio, 2007).  In a more recent survey in 2010, the National Center for Health Statistics 
approximated that 33,000 individuals, across the lifespan, received HPN (Winkler, et al., 2015).  
With the cost of HPN calculated to be around $652 million, HPN causes a financial burden on 
the health care system (Winkler, et al., 2015).  The financial burden is compounded further when 
other complications associated with HPN arise.  For instance, extant literature has shown that 
HPN patients’ experience not only physical complaints (e.g., diarrhea) but also psychosocial 
concerns related to their treatment.  While majority of the physical concerns can be resolved in 
the home environment, HPN patients’ psychosocial concerns, specifically depression, are left 
unaddressed (Baxter et al., 2006; Huisman-de Waal et al., 2006; Persoon et al., 2005).  These 
unaddressed psychosocial concerns accrue additional cost (around $80 billion), causing 
additional strain to the United States’ healthcare system (Howard, 2006).  Thus, to address 
depression within the HPN population, it is imperative that healthcare professionals are able to 
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detect depressive symptoms as they appear, so they may offset healthcare cost, reduce 
psychosocial concerns and improve quality of life among HPN users. 
      Detecting and addressing both physical and psychosocial concerns can be difficult with HPN 
users, particularly those receiving treatment outside of a hospital setting.  The advent of 
telemedicine as a potential mode of treatment has allowed healthcare professionals to treat 
patients in the home environment.  Telemedicine increases HPN users’ access to healthcare 
professionals (e.g., mental health specialists) and vital health care resources.  Thus, telemedicine 
reduces barriers to medical care.  However, questions remain about whether the absence of face-
to-face contact may limit the ability of healthcare professionals to detect psychological problems, 
like depression, particularly in chronically ill population.  Therefore, in the current study, we 
investigate whether it is feasible to assess depressive symptomatology during a telemedicine 
encounter with patients in the long-term HPN population. 
Background     
     Launched in the late 1960s, HPN, “a life-saving therapy,” was a treatment protocol prescribed 
to correct for dysfunction in the gastrointestinal tract through a formula solution delivered 
intravenously to the individual in their home environment (Howard Lyn J, 2002; Winkler, Ross, 
Piamjariyakul, Gajewski, & Smith, 2006; Winkler & Smith, 2014; Winkler & Guenter, 2014).  
This treatment ensures the body gains the necessary vitamins and nourishment to counteract 
malnutrition caused by the malabsorption of the gastrointestinal tract (Huisman-de Waal, 
Schoonhoven, Jansen, Wanten, & van Achterberg, 2007; Zhao et al., 2013). HPN requires the 
surgical insertion of a port and a Hickman line, a central venous catheter tunneled under the 
chest wall, which allows a feeding tube to be connected to a bag that contains nutritious aqueous 
solution for feeding (Baxter et al., 2006; Howard, 2002; Metzger, 2010). Before being released 
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from the hospital setting, HPN patients and caregivers are educated about the administration of 
HPN (Baxter et al., 2006; Metzger, 2010).  Healthcare professionals provide precise systematic 
instructions and training on the feeding process, which involves infusing an aqueous nutritional 
solution using an electronic pump.  HPN patients also learn aseptic techniques to create and 
maintain a sterile environment to care for their equipment (e.g., catheters, port, and pumps) and 
to avoid infections and other complications.  Overall, the process of administering HPN can 
cause undue burden upon patients as they are tasked to be hypervigilant and conscientious while 
performing their care in an effort to avoid dire consequences that can result in negative health 
outcomes, such as death. 
HPN is used to treat a variety of diseases that can cause malnutrition and malabsorption 
(Howard, 2006; Huisman-de Waal et al., 2007).  Duration of treatment with HPN varies by 
diagnosis (Howard, 2006).  For instance, surgical complications and enterocutaneous fistulae 
would require patient to undergo short-term HPN (< 1 year) with the end goal of restoring 
gastrointestinal function (Howard, 2002; Kirby, 2012).  However, HPN can be used “long-term” 
when gastrointestinal function cannot be restored.  Examples of primary diagnoses commonly 
associated to long-term HPN are inflammatory bowel syndrome, short-term bowel syndrome, 
Crohn’s Disease, and mesenteric ischemia (Howard, 2006; Persoon et al., 2005).  Inflammatory 
bowel syndrome and short bowel syndrome account for the majority of cases that require long-
term HPN (Baxter et al., 2006; Staun et al., 2009;Winkler et al., 2015;Winkler & Smith, 2014).  
Long-term HPN patients tend to be middle-aged patients who have a 90% survival rate on HPN 
(Howard, 2006; Winkler et al., 2015).  Nevertheless, long-term HPN patients show a reduction 




  Healthcare professionals have considered the employment of HPN to be cost-effective 
and beneficial to patients (Howard, 2006; Kim et al., 2014; Winkler et al., 2006; Zhao et al., 
2014).  HPN permits an earlier discharge from the hospital setting and allows patients to receive 
treatment at home (Zhao et al., 2013).  HPN, in turn, lowers healthcare costs because home care 
is typically less costly than hospital care.  For instance, HPN therapy expenses include the 
various components (e.g., dressing kits, nutrient solution, and infusion pump) that support 
treatment (Howard, 2006).  In a hospital setting, PN therapy includes not only direct costs (e.g., 
supplies, physician and laboratory services) but also indirect costs, including administration fees 
and floor space.  Investigators estimate that HPN therapy reduces healthcare costs about “30% - 
60%.”  With Medicare and Medicaid reimbursement for HPN therapy, expenses related to 
therapy have been estimated to “cut the total management cost by about half” and reduce cost to 
the individual.  Furthermore, HPN allows patients to receive treatment in a familiar environment 
and satisfy the patient’s nutritional needs while increasing survival rates about 15-25 years 
across the spectrum of diseases that result in its use (Persoon et al., 2005; Winkler et al., 2006).   
     Although HPN is a lifesaving procedure, the HPN can result in patients experiencing negative 
health outcomes with regard to not only their underlying condition but also the administration of    
HPN.  Commonly, HPN patients engage in a process where they infuse overnight and repeat the 
process on a 10-hour to 14-hour cycle.  This process often results in physical and psychosocial 
complaints—like fatigue, discomfort— as HPN patients must deal with interruptions to their 
sleep cycle because of the noise interference from their equipment and relevant fear of 
dislodging their catheters as they sleep (Chambers, Hennessy, & Powell-Tuck, 2006; Chambers 
& Powell-Tuck, 2007; Howard, 2006; Persoon et al., 2005; Winkler et al., 2006).  HPN patients 
also experience distress as HPN therapy may restrict activity to the home environment if they are 
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unable to manage feeding and maintaining a sterile environment outside the confines of their 
home.  Hence, HPN administration can cause drastic changes in daily routines in ways that can 
impair psychosocial functioning.  For example, HPN patients confined to the home environment 
may experience a decrease in social interaction and not be able to participate in previous 
pleasurable activities outside the home.   In turn, these complaints may result in a decrease in 
quality of life and increased occurrence of depression within this population (Howard, 2006; 
Winkler et al., 2006; Winkler, 2005).    
     As stated above, quality of life in the HPN population is considerably reduced compared to 
the disease- free population (Huisman-de Waal et al., 2007; Persoon et al., 2005).  Patients 
receiving HPN frequently report exhaustion, “loss of energy and optimism, fear”, apprehension 
due to the future, and concern about the underlying disease (Huisman-de Waal et al., 2007; 
Winkler & Smith, 2014).  HPN patients also reported a loss of independence and loss of 
engagement in previous activities (Baxter et al., 2006; Huisman-de Waal et al., 2006, 2007; 
Persoon et al., 2005).  Although seen infrequently, female HPN users have reported concerns of 
body image due to the ports and tunneled catheters implanted in the body (Baxter et al., 2006; 
Huisman-de Waal et al., 2007; Winkler & Smith, 2014).  These concerns may reflect the 
presence of or contribute to the high prevalence of depression reported by patients with HPN 
(Baxter et al., 2006; Huisman-de Waal et al., 2006, 2007; Persoon et al., 2005; Winkler & Smith, 
2014;. Winkler, 2005; Winkler & Guenter, 2014).  Another study conducted by Howard (2006) 
discovered a reduction in quality of life in those who rapidly transition from good health to using 
HPN and in those who are just beginning HPN treatment.  According to the author, factors that 
lowered quality of life were the following: “loss of employment,  loss of income, and decreased 
social interaction (Howard, 2006).”  These factors found in the study certainly contribute to 
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negative mood states leading to the increased diagnosis of depression disorder within the HPN 
population.  Consequently, HPN users are at a higher risk to experience a reduced quality of life 
due to HPN therapy than their healthy counterparts.  
      Researchers also have documented the presence of depression.  For instance, in a study 
conducted in the Netherlands, investigators assessed 48 HPN long-term users about issues that 
they faced while on HPN (Persoon et al., 2005).  HPN users reported decreased sleep functioning 
and anxiety.  Investigators also found that thirty-one individuals scored high enough on the Beck 
Depression Inventory checklist to classify as being at risk for a “depressive disorder.”  Thus, 
over half of the sample population endorsed depressive symptoms.  Patient interviews revealed 
that depression seemed to be linked to patients’ perceived inability to take care of themselves 
(Huisman-de Waal et al., 2007; Persoon et al., 2005).  Contributing to their negative mood states, 
participants indicated concern about their inability to engage in activities that were available to 
them before using HPN.  For instance, participants spoke about difficulties in enjoying social 
activities (e.g., a party) or traveling outside of the home due to their inability to eat.  As such, it 
is not surprising that HPN patients are documented within the literature as having an increased 
risk of experiencing depressive symptoms or associated negative mood states (i.e., anxiety and 
anger).    
     Since long-term HPN patients face an increased risk of depression and reduction of quality of 
life, healthcare providers should aim to increase monitoring and identifying the presence of 
depressive symptomology within this population.  Unfortunately, long-term HPN patients are 
commonly restricted to the home environment and experiences reduced access to mental 
healthcare providers.  Alternative avenues outside of traditional modes of treatment need to be 
used to assess for depressive symptomatology.  An available alternative avenue is telemedicine.  
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Telemedicine allows long-term HPN patients to have increased access to healthcare providers 
and the essential services they provide.  Moreover, investigators have demonstrated that 
telemedicine is comparable in its effectiveness to treat depression to traditional mode of therapy 
(i.e., face-to-face therapy)(De Las Cuevas, Arredondo, Cabrera, Sulzenbacher, & Meise, 2006; 
Khatri, Marziali, Tchernikov, & Shepherd, 2014; O’Reilly et al., 2007).  With long-term HPN 
patients designated by the federal government as being a technology dependent because of their 
reliance on technology (i.e., infusion pumps) for survival, this population has been primed to 
accept the introduction of  telemedicine, which should provide treatment support.  Indeed, 
researchers investigate the use of telemedicine within the HPN population have shown HPN 
patients to be amendable to utilizing videoconferencing as another avenue for treatment (Saqui et 
al., 2007; Smith et al., 2015).  This finding is supported in a recent study (Smith et al., 2015), 
where researchers found  HPN patients  as well as healthcare professionals willing to 
communicate utilizing videoconferencing through the use of mobile health technology (Smith et 
al., 2015).  Using telemedicine to identify and monitor depressive symptoms within this 
population is a feasible solution for both healthcare professionals and HPN users.  
Theoretical Model 
     To accurately access the feasibility of utilizing telemedicine to identify depressive 
symptomatology compared to traditional modes (face- to- face), a framework that assesses the 
effectiveness of telemedicine interventions was used to guide the current study.  The Model for 
Assessment of Telemedicine (MAST) is a popular framework used in Europe to evaluate the  
application of telemedicine interventions (Kidholm et al., 2012).  The MAST framework has 
three major components: (1) preceding consideration, (2) multidisciplinary assessment, and (3) 
assessment of transferability.  The preceding consideration component comprises of identifying 
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the purpose in which the technology shall be used and if the technology is sufficiently developed 
to support the intervention.  The multidisciplinary component includes the following domains (1) 
health problem and characteristics of the application, (2) safety, (3) clinical effectiveness, (4) 
patient perspectives, (5) economic aspects, (6) organizational aspects, and (7) social-cultural, 
ethical, and legal aspects.  The last component transferability refers to extrapolating the 
intervention to other settings and populations.  The current study meets the preceding 
consideration criteria as we have demonstrated a clear purpose for utilizing developed 
technological resources on a national level.  The focus of the current study explores in depth the 
multidisciplinary component, specifically the clinical effectiveness of utilizing of telemedicine to 
identify symptoms of depression.  
      Extant research has shown telemedicine being effective in treating depression in different 
medical populations (e.g., pain, diabetes, and disability); however, limited evidence exists in 
identifying depressive symptoms using telemedicine  versus traditional diagnostic tools, such as 
structured interviews and self-report measures (Baron, Hirani & Newman, 2016; Chavooshi, 
Mohammadkhani, & Dolatshahee,  2016; Choi, et al., 2014; Mochari-Greenberger, 2016; 
Salisbury, et al., 2016).  To assess whether telemedicine can identify depressive symptoms, the 
current study has modified an existing validated scale, the Raskin Three- Area Severity of 
Depression rating scale (see Appendix A).  Currently, the modified scale is the best option to 
detect depressive symptoms through telemedicine since it allows for easier detection of 
depressive symptoms within an unstructured interview.  Hence, using the modified scale allows 
the current study to explore not only whether depressive symptoms can be in identified through 
telemedicine but also add to the existing literature regarding the efficacy of telemedicine versus 




Data for this study came from a larger clinical trial designed to demonstrate the receptiveness of 
HPN users to telemedicine as a mode of treatment (Smith, et al., 2015). The purpose of the 
current study was to extend Smith, et al.’s findings by assessing the feasibility of utilizing 
telemedicine- a technology- supported platform- to identify depressive symptomatology within 
long-term HPN population.  As reported in the literature, long-term HPN patients experience an 
increased risk of depression and tend to be confined to the home environment.  As such, long-
term HPN patients would benefit from increased monitoring for the earlier identification of 
depressive symptoms to improve quality of life and HPN treatment.  Building from the extant 
literature and theoretical framework, it was hypothesized that telemedicine would be a viable 
mechanism by which trained medical professionals could monitor and identify of depressive 
symptomatology within the long-term HPN population.  Hence, we expected that healthcare 
professionals using telemedicine would be able to identify depressive symptoms effectively.  
Aims of this study are specified below. 
Aims 
     Study Aim 1: To assess the interrater reliability of the modified Raskin in rating the presence 
of depressive symptoms amongst raters.  Statistical Package for Social Sciences -22 (SPSS-22) 
software packages will be utilized to calculate the appropriate statistical test, kappa, and to 
confirm interrater reliability.      
     Study Aim 2: To establish the criterion validity of the Raskin scale.  We hypothesized that 
raters would be able to identify depressive symptoms utilizing the modified Raskin scale. Raskin 
items were compared to self-report.  Analysis included creating an overall sum for the Raskin 
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scale and utilized SPSS to conduct an Ordinary Least Squares (OLS) regression to examine 
whether the Raskin scale predicted the presence of depression as indicated by the patient 
reported PHQ-9.            
     Study Aim 3: To identify items on the modified Raskin scale that correlated strongly and 
poorly with the PHQ-9 scores.  Content analysis was used to identify categories of symptoms as 
identified by the Raskin scale: behavioral symptoms (e.g., crying, poor eye contact, fidgeting), 
verbal report (e.g., limited speech production, complains of loss energy), and secondary 
symptoms (e.g., complaints of insomnia, change in appetite).  We hypothesize that secondary 
symptoms from the modified Raskin scale would correlate poorly and behavior symptoms and 
verbal report from the modified Raskin scale would correlate strongly with the PHQ-9.   
Methods 
     The dataset presented in the current study was procured from a clinical trial study proposed 
by Carol Smith, Ph.D. and funded by the National Institutes of Health (NIH) and registered on 
the USA Clinical Trials.gov as Registration # NCT0190028.  The NIH clinical trial enrolled 126 
participants to examine the feasibility of telemedicine (mobile technology) to provide health care 
services to long-term HPN users and caregivers as well as assist this population with self-care 
and coordinating that care with other healthcare professionals.  The Institutional Review Board at 
the University of Kansas Medical Center approved the original study and confidentiality has 
been kept with all patient information (i.e., videos) kept on a secure drive. 
Participants 
          Researchers recruited participants through the University of Kansas Medical Center, 
associated rural health centers, and the Oley Foundation.  Participants were eligible to participate 
11 
 
if they were HPN user and had a caregiver (non HPN- user) who agreed participate in the study, 
fluent in English, and able to provide informed consent.  Exclusion criteria included any 
participants that had a disability or disorder that prevented them from using a mobile tablet.  In 
the current study, participants were excluded if they were below the age of 18 (n=2), did not 
participate in the facilitated group discussion (n=2), were not a HPN user (n=38) or in the control 
group (n=59).   
Questionnaires 
     Demographic Questionnaire. Participants completed a demographic questionnaire that 
collected information about income, insurance, and participants’ use of HPN (e.g., reasons for 
HPN and duration of HPN).       
    Patient Health Questionnaire-9 (PHQ-9).  PHQ-9 (Kroenke, Spitzer, & Williams, 2001) is a 
nine- item questionnaire that asks respondents to respond to items such as  I have “little interest 
or pleasure in doing things” on a four- point, Likert scale.  The PHQ-9 was created to monitor 
and/ measure the severity of depressive symptomatology and has shown excellent internal 
reliability (alpha = 0.89) and test-retest reliability.  The PHQ-9 has also shown excellent 
discrimination between individuals with depression and individuals without depression.  
Kroenke, et al. (2001) demonstrated that the PHQ-9 has good criterion validity with regard to its 
ability to identify and predict depressive symptoms.  Kroenke, et al. also demonstrated good 
construct validity with the PHQ-9 strong relationship between “functional status, disability days, 
and symptom-related difficulty” (2001).       
     Raskin Three- Area Severity of Depression Rating Scale (Raskin scale). Before selecting 
the Raskin scale, the author reviewed the literature and consulted with depression experts on 
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depressive measures (e.g., Beck Depression Inventory-II, Montgomery-Asberg Depression 
Rating) that would allow for an observational assessment of depressive symptoms through an 
unstructured interview.  The majority of the traditional depressive measures for adults relied on 
either self-report or a structured/ semi-structured interview conducted by the clinician to identify 
depressive symptomatology. However, the current study required a measure that could be used to 
rate symptoms of depression as they presented themselves in an unstructured group setting, 
rather than in a structured interview. 
     The Raskin scale (Raskin, Schulterbrandt, Reatig, & McKeon, 1970) was designed as an 
observer rater scale to measure changes in depressive symptoms of depressed individuals 
undergoing pharmacological treatment.  The Raskin scale examines depression symptoms in 
three major areas— verbal report (e.g., feels blue, reports of crying spells), behavior (e.g., looks 
sad, lacking energy), and secondary symptoms (e.g., insomnia, change in appetite) with 
examples anchoring in each area. Raters rate the degree of severity from one (not at all) to five 
(very much), for each area.  Thus, scores can range from three to 15 points to demonstrate the 
severity of the depression.  Psychometric properties of the measure are limited; however, studies 
have shown the Raskin to have acceptable interrater reliability (.88 for the entire scale), good 
sensitivity but poor specificity (Fish, 2011; Nezu, et. al., 2000).  The Raskin scale was selected 
because it differs from self-report and interview measures in that multiple sources of information 
(i.e., interview, patient self-report, or collateral information provided by others) are used to 
inform the assessment of depression symptom.  This may make the Raskin the best option for an 
observer rating scale when interview data are not available. 
     The Raskin scale (see Appendix A) was modified to identify the presence of depression rather 
than the severity of a depressive mood.  When modifying the Raskin scale, the author added 
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depressive symptoms specified by the Diagnostic Statistical Manual- 5 (DSM-5) and from the 
existing literature (Cummins, et al., 2015; Foley & Gentile, 2010).  The author added the 
following symptoms in the Verbal Report domain: limited speech production and complaints of 
loss energy or fatigue; in the Behavioral Symptom domain: poor eye contact and flat facial 
expression; and Secondary Symptom domain: self-focus, previously reported depression and 
optional symptoms (i.e., sleep disturbances).  An additional modification was made to the rating 
scale.  Instead of rating each domain on a Likert scale, raters were asked to code the presence of 
the symptom under each domain by marking the presence of a symptom, a yes (1) or no (0), and 
tabulating the number of times the symptom occurred.  Thus, the modified Raskin score could 
have ranged from 0-294.  In practice, however, the items on the modified Raskin scale ranged 
from 0-4.     
Procedure 
     As part of the original study, participants were sent a wireless touch-screen mobile Apple 
iPad Mini
TM
 tablet (iPad).  The iPad included a fourth generation (4G) unlimited data plan and a 
five mega-pixel camera that provided clear visual properties for participants.  Polycom 
RealPresence encrypted software was installed onto the iPads to allow for secure 
videoconferencing between health professionals and participants.  Participants completed a 
PHQ-9 questionnaire and engaged in a facilitated group discussion at baseline (T1).  Participants 
then completed another PHQ-9 questionnaire a month after the facilitated group discussion (T2).  
    To assess whether depressive symptoms could be identified through videoconferencing, three 
raters reviewed 28 facilitated group discussions that were videotaped by an iPad.  Raters were 
graduate students from the University of Kansas Clinical Psychology program with clinical 
experience in identifying depression.  Raters underwent training in using the modified Raskin 
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Scale and were blinded to both PHQ-9 scores at T1 and T2.  With the modified Raskin scale, 
raters recorded the presence of a specific symptom (e.g. poor eye contact) with a yes or no and 
tabulated the number the times that specific depressive symptom occurred.  If raters reported 
difficulty with identifying or tabulating the presence of a depressive symptom, the other two 
raters were consulted.  Videotapes were reviewed and discussed until all raters arrived at a 
consensus about the presence/absence of a depressive symptom.   
Data Analysis 
     Statistical analyses were conducted using the Statistical Package for Social Sciences -22 
(SPSS-22) software packages.  To examine interrater reliability, interclass correlation 
coefficients (ICC) were calculated (Koo & Li, 2016; Shrout & Fleiss, 1979).  Criterion validity 
was assessed by comparing the modified Raskin scale to the PHQ-9 at T1 and T2.  An overall 
sum was created for the modified Raskin scale.  An OLS was conducted to determine whether 
the modified Raskin scale correlated with patient reported depression symptoms on the PHQ-9 
score at T1 and T2.  Zero order correlations were examined to evaluate the relationship between 
subscales of the Raskin—Verbal Report, Behavioral Symptoms, and Secondary Symptoms and 
the total PHQ-9 score (T1 and T2). 
Results 
Characteristics of the sample 
     Twenty-five patients between the ages of 19-71 (M=41.76, SD= 14.36) were included in the 
analyses at T1.  Participants were predominantly female (88%), Caucasian (96%), and were on 
HPN for at least two years (44%).  See Table 1 for further description of the baseline 
demographics of the sample.  Four patients out of the 25 patients from T1 were excluded from 
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analyses at T2 for the following reasons: three patients did not complete the PHQ-9 
questionnaire at T2, and one participant died.  We found no differences between those who 
completed the study and those who dropped out of the study. 
Study Aim 1 
    To assess the interrater reliability of the modified Raskin scale, three clinical psychology 
graduate students rated three long-term HPN users on the modified Raskin scale after training. 
Interrater reliability was calculated using ICC.  We used a two-way random effects model to 
examine the average measurement and absolute agreement between the raters (Koo & Li, 2016). 
The interrater reliability was found to be good to excellent amongst raters, ICC (2, 3) = 0.96 with 
a 95% confidence interval=0.83-0.999, F (2, 8) = 3.03, p<.05.  
Study Aim 2  
     An OLS regression analysis was used to determine whether the total of the modified Raskin 
scale predicted self-reported depression symptoms as identified by the PHQ-9 at T1 (Table 2).  
The results indicated that the modified Raskin scale explained .8% of the variance [R
2
=.008, F 
(1, 23) =1.88, p =.669] in the PHQ-9 at T1.  In other words, there was no relationship between 
the modified Raskin scale and PHQ-9.  Thus, the modified Raskin scale did not predict the 
presence of depression as measured by the PHQ-9.  A second OLS analysis was performed to 
determine whether the modified Raskin scale predicted the presence of depression as identified 
by the PHQ-9 scores at T2.  The results indicated that the modified Raskin scale explained 
46.5% of the variance [R
2
=.465, F (1, 19) = 16.486, p< .01].  It was found that the modified 
Raskin scale significantly predicted self-reported depression symptoms as identified by the PHQ-
9 (β=.682, p<.01).   
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     A follow-up analysis examined whether the difference between T1 and T2 was due to the loss 
of the four patients from T1.  We removed the four patients lost at T2 and re-ran the OLS 
regression equation at T1 to determine whether that changed the relationship between the 
modified Raskin scale and PHQ-9 at T1.  The results were essentially unchanged.  The modified 
Raskin scale explained 3.5 % of the variance [R
2
=.035, F (1, 19) =.681, p =.419] in the PHQ-9 at 
T1.  Thus, the difference in the relationship between the Raskin scale and PHQ-9 at T1 and T2 
was not an artifact of patient attrition.  
     Finally, in a second follow-up analysis  we used an OLS regression analysis to determine 
whether the PHQ-9 at T1 or the modified Raskin scale at T1 predicted depressive symptoms at 
T2 after controlling for  PHQ-9 at T1 (Table 3). The results indicated that PHQ-9 at T1 and the 
modified Raskin scale accounted for 67.9% of the variance [R
2
=.679, F (2,18)= 18.997, p<.01)].  
Both the PHQ-9 at T1 (β=.471, p<.01) and the modified Raskin scale (β=.594, p<.01) 
significantly predicted depressive symptoms as identified by the PHQ-9 at T2.  
 Study Aim 3 
     Pearson correlations were calculated between the domains—Verbal Report (VR), Behavioral 
Symptoms (BS), and Secondary Symptoms (SS)—of the modified Raskin scale and the PHQ-9 
scores at T1 and T2 (Table 4).  Nonsignificant Pearson correlations were found between all the 
domains of the Raskin and PHQ-9 at T1 (p=ns).  However, significant Pearson correlations were 
found between the PHQ-9 at T2 and two of the Raskin subscales at T2 VR (r=.463) and SS 
(r=.659) and PHQ-9 at T2.  
     Follow-up analyses were conducted to identify specific Raskin items that correlated with the 
self-reported depression.  Specifically, we examined zero-order correlations between the PHQ-9 
17 
 
at T1 and T2 and individual items from the modified Raskin scale (Table 5).  Significant 
relationships exist between PHQ-9 at T1and “appears restless” (BS) (r=.405) and “previously 
reported depression” (SS) (r=-.509).  Significant correlations exist between the PHQ-9 at T2 and 
“complains of loss energy or fatigue” (VR) (r=.474), the “complaints of insomnia” (SS) (r=.457), 
“self-focus” (SS) (r=.514), and optional symptoms (i.e., sleep disturbances) (SS) (r=.531). 
Discussion 
     HPN is a common treatment that allows patients to receive competent care in the comfort of 
their own home, improving quality of life.  However, patients on HPN lack the daily in person 
interaction with healthcare professionals, which may cause delay in identifying symptoms of 
depression by healthcare professionals.  Thus, the purpose of the current study was to determine 
whether symptoms of depression could be identified over a video-supported platform utilizing an 
observer rating scale (i.e., the modified Raskin scale) as a way to avoid the delay caused by the 
lack of face-to-face interactions between patients and healthcare professionals.  The results of 
this study suggest strong interrater reliability and mixed preliminary evidence regarding the 
criterion validity of the modified Raskin scale in identifying depressive symptoms over a video-
supported platform compared to the PHQ-9.  
     The first AIM of this study was to assess the reliability of the Raskin scale.  The interrater 
reliability as assessed by the ICC indicated that the raters were good to excellent in identifying 
depressive symptoms utilizing the modified Raskin scale, which supported our initial hypothesis. 
Documenting inter-rater reliability for an observer rating scale is of critical importance because 
the scale relies on the subjective interpretation and judgement of multiple raters.  As such, 
multiple raters introduce measurement error, which negatively affects how well an observer 
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rating scale assesses the intended construct (e.g., depression) (Hallgren, 2012).  We can 
reasonably assume that our use of multiple raters did not add excessively to the measurement 
error and compromise our ability to identify depressive symptoms using the modified Raskin 
scale.  
     The second and third AIMs of this study were to establish evidence of criterion validity by 
comparing the Raskin rating scale to an established self-report measure of depression symptoms.  
We predicted that the modified Raskin scale would be comparable to the self-report measure, 
PHQ-9, in detecting depressive symptoms.  Unfortunately, there was little relationship between 
the total Raskin scale and the PHQ-9 at T1, indicating that these two measures of depression may 
not be measuring the same thing. Subdomain analysis proved similarly disappointing results.  
We had predicted that the two most objective domains of the Raskin that were based on 
observations of behaviors and verbal reports would have a stronger relationship to the PHQ-9 
than the more subjective, secondary symptom domain.  It is noteworthy, however, that although 
the relationship between behavioral symptoms and the PHQ-9 was not statistically significant, 
the effect size was much larger than the effect sizes of the relationship between the PHQ-9 and 
verbal reports or secondary symptoms (Refer to Table 4).  
     Interestingly, although there was no relationship between the Raskin subscales and the PHQ-9 
at Time 1, we found that the modified Raskin scale was able to predict depressive symptoms 
when compared to the PHQ-9 at T2.  Hence, our findings suggest that while raters demonstrated 
excellent interrater reliability the modified Raskin scale demonstrated evidence of poor 
concurrent validity and strong predictive validity.  To ensure that this was not an artifact because 
of the loss of patients in T2, we re-analyzed the data at T1 excluding the four patients lost at T2. 
We found the same non-relationship between the modified Raskin and the PHQ-9 at T1 that was 
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seen in our earlier analysis, meaning that the loss of patients was not an artifact that caused our 
significant finding at T2.  
     There are several explanations for our mixed findings.  One possible explanation is that the 
psychometric properties of the original Raskin scale are still evident in the modified Raskin 
scale.  For instance, although the original Raskin scale had good sensitivity, the scale 
demonstrated poor specificity.  Thus, our ability to differentiate depressive symptoms from 
symptoms of the illness may be compromised.  Indeed, raters may mistakenly code illness 
behaviors as indicative of depression, which may be affecting the measure’s concurrent validity.   
     An alternative explanation could be that the PHQ-9 overestimates the presence of depression 
symptoms.  The current sample was comprised of patients with critical illnesses that necessitate 
the use of HPN.  Long-term HPN users experience physical symptoms (e.g., fatigue and weight 
loss) as result of their treatment that are not due to psychological cause.  For example, the PHQ-9 
has three questions that ask specifically about fatigue, appetite, and sleep.  However, long-term 
HPN users are unlikely to be able to distinguish the presence of a symptoms caused by HPN as 
opposed to a psychological origin.  Because we did not have a gold-standard diagnostic 
interview, it is not possible to determine which measure over or underestimated the presence or 
severity of depression. Additionally, we must consider the impact of the group dynamics and its 
influence on rating the PHQ-9 at T1 and T2. HPN patients might have felt more comfortable in 
disclosing depressive symptoms on the PHQ-9 at T2 as they became comfortable with the 
study’s team.  
     Consistent with AIM 3, we examined the correlation between the Raskin subscales and the 
PHQ-9 total score.  Given that we were comparing observations to self-reports, we hypothesized 
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that the more objective Raskin scale domains, VR and BS, would have stronger correlations with 
the PHQ-9 than the more subjective secondary symptom subscale.  Consistent with the overall 
score, we saw the same pattern at T1—weak non- significant concurrent relationships between 
the modified Raskin subscales and the PHQ-9.  However, we saw significant correlations 
between the modified Raskin scale domains to the PHQ-9 at T2.  Surprisingly, the pattern of 
relationships was not as expected.  The strongest relationship was between SS and the PHQ-9 at 
T2.  VR was also a significant predictor of the PHQ-9 at T2.  However, the BS domain had a 
non-significant relationship with the PHQ-9 at T2.  We expected the behavioral domain to be 
easier to rate than the other domains.  However, raters reported difficulty in rating behavioral 
symptoms because of the nature of the video-supported platform.  Meaning, raters noted 
technical difficulties (i.e., poor video quality, constant moving of mobile tablet) that hindered 
their ability to successfully rate behavioral symptoms.  In contrast, VR and SS relied on 
participants reporting symptoms, which were not influenced by video quality.  Participants 
mostly reported sleep disturbances, fatigue related to their use of HPN.  They also discussed 
weight loss and gain in reference to their use of HPN.  Participants did talk about depressive 
symptoms. However, they usually reported such symptoms that had occurred in the past.  Thus, 
VR and SS were easier to rate than BS, which may explain why VR and SS had a positive, 
significant relationship, but BS was not related to PHQ-9 at T2.  
Refining the Raskin Scale   
     Overall, the modified Raskin scale demonstrated a poor ability to identify depressive 
symptoms compared to the PHQ-9 when administered simultaneously at T1.  Hence, the PHQ-9 
an inexpensive self-report measure seems to be a more appropriate tool than an observer rating 
scale—a disappointing finding considering that self-report measure may not be feasible when 
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interactions occur over a video-supported platform.  However, we found that the modified 
Raskin scale has utility in predicting depressive symptoms at T2, specifically, the VR and SS 
domains of the modified Raskin scale.  Given these findings, it seems appropriate to explore 
whether the modified Raskin scale could be refined to increase its utility in identifying people at 
risk for increased symptoms of depression or onset of an episode of depression.  
     Subsequent analysis identified a few significant relationships between individual items on the 
modified Raskin scale and the PHQ-9 at T1 and T2 (Refer to Table 5).  Although a weak 
relationship existed between the modified Raskin scale and the PHQ-9 at T1, it is interesting to 
note that, “appears restless” and “previously reported depressed,” had a strong, positive 
relationship with the PHQ-9 at T1.  T1 observations: “complains of loss energy or fatigue”, 
“complaints of insomnia”, and behavioral observations of “self-focus”, and “optional 
symptoms”—demonstrated a strong relationship with the PHQ-9 at T2.   
     In examining individual items from the modified Raskin scale, we found it noteworthy that 
“self-focus” demonstrated a strong relationship with depressive symptoms as identified by the 
PHQ-9 at T2.  Introduced by social psychologists in the seventies, self-focused attention has 
been documented in the literature to be closely related to depression (Ingram, 1990; Mor & 
Winquist, 2002; Pyszcynski, Hamilton, Herring, & Greenberg, 1989).  Indeed, researchers have 
argued that depressed individuals engage in self-focused attention as a form of rumination, which 
is characteristic of depressed individuals.  Self-focused attention as a form of rumination 
appeared to be supported by our current findings as self-focus predicted that HPN patients, who 
focused more on themselves at T1, would exhibit an increase in depressive symptomatology in 
T2.    
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     Our results suggest that the modified Raskin scale was sensitive to self-reports of vegetative 
symptoms (e.g., insomnia) and behavioral-related depressive symptoms (e.g., talking only about 
themselves) reported by patients.  The data also suggest that these items from the modified 
Raskin scale were strong predictors of depression at T2.  As such, the modified Raksin scale 
could be reduced to these items to lessen the observation burden.  Although it may be beneficial 
for patients to continue self-reports of depressive symptoms at baseline, using the modified 
Raskin scale may provide its greatest utility in predicting future depressive symptomology.  
Meaning, healthcare professionals may identify individual patients, who may not directly report 
these behaviors (e.g., vegetative, behavioral-depressive symptoms) at baseline, but would 
warrant further monitoring and support in treating depression symptoms in the future.    
        Surprisingly, the modified Raskin scale was not only a predictor of future depressive 
symptoms as indicated by the PHQ-9 score at T2 but a stronger predictor than the PHQ-9 score 
at T1 (Refer to Table 3).  This is an interesting finding considering that the PHQ-9, an 
empirically validated measure of depression, was expected to be a stronger predictor of itself 
(PHQ-9 score at T2) than the modified Raskin scale.  We posit that the modified Raskin scale as 
an observer rating scale allows professionals to identify vegetative, behavioral-depressive 
symptoms that are more indicative of a future experience of depression.  Although PHQ-9 
consists of questions regarding vegetative, behavioral depressive symptoms, it is dependent on 
patients’ understanding as well as willingness to endorse these items.  Alternatively, the 
modified Raskin scale allowed for a more refined assessment of these vegetative and behavioral 
symptoms as raters were not reliant on self-report but rather able to identify and objectively code 
for these behaviors. 
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        The current study was the first to assess the ability to identify depressive symptoms over a 
video-supported platform with a screening tool that does not depend upon self-report or a 
structured interview.  Thus, the study adds to the existing literature by providing a behavioral-
rated measure utilized by healthcare professionals to detect depressive symptoms.  By accurately 
and quickly identifying depressive symptomatology through a video-supported platform, we 
would be able to offer better treatment of depressive symptoms and have positive long-term 
health outcomes for the chronically ill population.  The results of this study show that the 
modified Raskin scale was a reliable assessment of symptoms that may have predictive but not 
concurrent validity.  Further studies focusing at the item level may improve both the validity of 
the scale and reduce the rater burden.  Additionally, when examining the scale validity, studies 
also should examine the scale’s ability to identify depressive symptomatology in different 
populations (i.e., older adults and ethnic, racial minorities) for further utility. 
Limitations  
There were a number of limitations that limit conclusions that can be drawn from this 
study.  First, sample size limited power to detect significant relationships.  Only twenty-five 
individuals were included in the analysis.  In addition, because we included only long-term HPN 
users and excluded caregivers, we potentially restricted the range of symptomatology.  Another 
limitation was the psychometric properties of the modified Raskin scale.  The modified Raskin 
appeared to have poor specificity, perhaps an artifact left over from the original scale that 
potentially influenced the results. Both the modified Raskin scale and PHQ-9 are limited in 
detecting and differentiating between grief and reactive depression, which are common within 
the HPN population.  Thus, this inability to differentiate between reactive depression, grief, and 
“true” depression could influence and limit how the PHQ-9 and modified Raskin scale’s ability 
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to provide an accurate presentation of depressive symptomatology within this population. 
Finally, rating was compromised by the poor video quality, a limitation that made rating 
symptoms to be difficult.  Since telemedicine relies partly on the use of a video-supported 
platform, the need for a clear, steady picture and audio is essential. Healthcare professionals 
interested in using a video-supported platform will continuously face various technical 
complications (e.g., poor video quality) that can cause difficulties in diagnosis and treatment of 
their patients.  The PHQ-9 and the modified Raskin scale both dispA critical and final limitation 
of this study was the use of the PHQ- 9 as the criterion measure.  The PHQ- 9 is a measure of 
depressive symptomatology and cannot be used to replace a clinical interview.  Thus, the results 
reported here are ambiguous. Without a true criterion measure, it is impossible to know whether 
the PHQ-9 or the modified Raskin is a more accurate assessment of depressive symptomatology.     
Conclusion 
        Our ability to identify depressive symptoms over a video-supported platform requires 
ongoing investigation, particularly in examining the psychometric properties of the modified 
Raskin scale.  Investigators should examine the modified scale to improve and increase internal 
consistency and criterion-related validity.  With a measure that could aid in early identification 
and monitoring of depressive symptoms, clinicians along with untrained healthcare professionals 
may make better use of technology as a mode of treatment and increase the positive long-term 
health outcomes for the chronically ill population, who may depend upon the use of 
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Characteristics of Long-Term HPN Users 
Characteristics  n(%) M (SD) 
Sex   
     Males 3 (12%)  
     Females 22 (88%)  
Ethnicity   
     Hispanic 2 (8%)  
     Non-Hispanic 23 (92%)  
Race   
     White 24 (96%)  
     Black 1 (4%)  
Age  41.76 (14.36) 
HPN Years  2.76 (.926) 
     1 1 (4%)  
     2 11 (44%)  
     3 6 (24%)  
     4 7 (28%)  
Education   
     Some high school/Currently in high  school 1 (4%)  
     Some college/Currently in college 6 (24%)  
     Completed college or more 18 (72%)  
Marital Status   
     Married 9 (36%)  
     Divorced 5 (20%)  
     Separated 1 (4%)  
     Never Married 10 (40%)  




     1 person 3 (12%)  
     2 people 8 (32%)  
     3 people 8 (32%)  
     4 people 4(16%)  
     5 people 2 (8)  
Modified Raskin Scale   3.28(3.458) 
PHQ-9 at T1 25 7.88 (5.464) 
PHQ-9 at T2 21 7.76 (5.638) 







Summary of Ordinary Least Square Regression Analyses for the Modified Raskin Scale 
Predicting PHQ-9 at T1 and T2 
         PHQ-9  
 
Variable 
T1 (n=25)  T2 (n=21) 
β  t P 95% CI β t p 95% CI 
Constant  
 
 4.791 .000 [4.21, 
10.61] 
 3.336 .003 [1.58, 6.89]** 
Modified Raskin Scale .090 .434 .669 [-0.54, 
0.82] 
.682** 4.060 .001 [0.51, 0 .58]** 






















Summary of Ordinary Least Square Regression Analyses for the Modified Raskin Scale and 
PHQ-9 at T1 Predicting PHQ-9 at T2 
 PHQ-9 at T2 (n=21) 
Variables β  t P 95% CI 
Constant  
 
.774 .449      [-1.810, 3.923] 
PHQ-9 at T1 .471 3.46 .003 [0.193, 0.790]** 
Modified Raskin Scale .594 4.37 .000 [0.472, 1.348]** 























Correlation of Domains of the Modified Raskin Scale, Modified Raskin Scale Total, and PHQ-9 
at T1 and T2 












Variables M(SD) 1 2 3 4 5 6 
1. PHQ-9 at T1 7.88(5.46) –      
2. PHQ-9 at T2 7.76(5.64) .58** –     
3. Verbal Report .84(1.60) .01 .46* –    
4. Behavioral Symptoms .56(1.12) .33 .38 -.09 –   
5. Secondary Symptoms 1.88(1.90) -.04 .66** .71** .13 –  


























































































The Modified Raskin Scale 













Limited speech production 
-Participant rarely spoke to others. If person spoke, 
it was short brief sentences. 
  
 








Reports Depressed Mood 




Wishes to be Dead 
-Participant reports suicidal thoughts/ or makes 
mentions of being better off dead/ or shows 
preoccupation with death. 
  
 
Reports Crying Spells 
-Participant mentions crying because they are sad 
and upset.  
  
 
Complains of loss energy or fatigue 
- Participant gives multiple reports of being tired 
















- Participant is visibly crying.  
  
 
Poor Eye Contact 
- Participant does not make eye contact when being 
spoken too, nor does the person make eye contact 







Speaks in low voice (Depressed Mood) 




Movements are slow 
- Participant tends to moves slow on camera or 
reports doing so. 
  
 





- Participant appears to fidget within their seat and 









Complaints of Insomnia 
- Participant reports unable to sleep. 
  
 
Complaints of Hypersomnia 
- Participant reports sleeping all the time. 
  
 
Reports recent change in appetite 








- Participant does not offer advice or tend to be 
self-focused upon themselves.  
  
Previously reported depression  
-Participant reported that they felt depressed before. 
  
Optional Symptoms 
-Participant reports sleep disturbances. 
  
